Levi & Korsinsky announces it has commenced an investigation of AngioDynamics, Inc. (“AngioDynamics” or the “Company”) (NASDAQ: ANGO) concerning possible violations of federal securities laws.

On July 17, 2017, AngioDynamics filed a Form 8-K with the Securities and Exchange Commission disclosing that, among other things, its former independent registered public accounting firm has “determined that there was a material weakness in the Company’s internal control over financial reporting as of May 31, 2016 because the Company did not design and maintain effective internal controls over the accounting for the annual goodwill impairment test.” Following this news, AngioDynamics stock fell 6.78% to close at $15.12 per share on July 18, 2017. To obtain additional information, go to:

http://www.zlkdocs.com/ANGO-Info-Request-Form-5951

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.